Knocking on the door

The U.S. biotech wants a bigger offer before talking. The French pharma group, meanwhile, has gone public with its lowball $69ashare offer, hoping to pressure its target into talks that might yield a higher price. But Sanofi’s threat of a hostile bid looks hollow for now.